A COVID-19 vaccine developed by scientists at Oxford University is safe and has produced an immune response in early-stage clinical trials in healthy volunteers, preliminary results say.
Key points:
- The experimental vaccine, called AZD1222, was administered to healthy adults aged 18-55 years with no history of COVID-19
- It did not prompt serious side effects and produced antibody and T-cell immune responses
- Several countries have signed agreements with AstraZeneca to produce the vaccine
The vaccine, called AZD1222 and under development by AstraZeneca and scientists at Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal. The strongest response was seen in people who received two doses.
“We hop